Navigation Links
Susan G. Komen for the Cure(R) Announces Recipients of 2008 Komen Brinker Award for Scientific Distinction
Date:12/4/2008

DALLAS, Dec. 4 /PRNewswire/ -- Two researchers who translate math into better patient care and one scientist focused on stopping breast cancer in its tracks are this year's winners of the Komen Brinker Award for Scientific Distinction in basic research and clinical research. They will be honored Dec. 11 in San Antonio, Susan G. Komen for the Cure(R) announced today.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO)

Award recipients will be formally recognized during the 31st annual San Antonio Breast Cancer Symposium (SABCS), a major international gathering of breast cancer researchers, clinicians and patient advocacy organizations, held Dec. 11-14 in San Antonio, Texas. The three recipients will deliver lectures for SABCS attendees at 4:15 p.m.Dec. 11 in Exhibit Hall D of the Henry B. Gonzalez Convention Center. Each will receive a cash award of $25,000 and a crystal award.

    WHAT:   Komen for the Cure honors researchers at San Antonio Breast Cancer
            Symposium

    WHEN:   Thursday, Dec. 11, 2008, 4:15 p.m.

    WHERE:  Henry B. Gonzalez Convention Center, Exhibit Hall D.

    WHO:    Patricia Steeg, Ph.D. Chief of Women's Cancers Section, Center for
            Cancer Research, National Cancer Institute; Richard Gelber, Ph.D.
            Professor of Pediatrics (Biostatistics), Harvard Medical School;
            Aron Goldhirsch, M.D. Director of the Dept. of Medicine, European
            Institute of Oncology, Milan, Italy.

    EXTRAS: Awardees, Komen's CEO and Chief Scientific Advisor available for
            interviews

About Susan G. Komen for the Cure(R)

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure(R) and launch
'/>"/>

SOURCE Susan G. Komen for the Cure
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. PRA International Adds Dr. Susan Stansfield as Executive Vice President
2. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
3. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
4. Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer
5. Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure
6. PNY Technologies and Susan G. Komen for the Cure Partner to Raise Awareness of Breast Cancer
7. Susan G. Komen for the Cure Partners With the Original Butter Bell(R) Crock Developer
8. Susan G. Komen for the Cures Phoenix Affiliate, State Officials, Survivors and Advocates Call for Action on Breast Cancer
9. Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries
10. In Celebration of Breast Cancer Awareness Month, Susan G. Komen for the Cure San Diego Announces Opportunities for San Diegans to Get Involved in the Fight Against Breast Cancer
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Dennis Thompson HealthDay ... -- Hospitals that pull out all the stops to ... saving lives, but the cost of such heroism is ... are about 5 percent better at saving elderly patients ... that operate with less intensity, said senior author Dr. ...
(Date:10/2/2014)... by scientists at The University of Nottingham could lead ... painkiller. , A drug resulting from the research, published ... offer new hope to sufferers of chronic pain conditions ... painkillers are currently available. , The work, led by ... Sciences, in collaboration with David Bates, Professor of Oncology ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... in the Journal of the American Medical Association ... with moderate or severe chronic knee pain, acupuncture did ... of Melbourne randomly assigned 282 patients (50 years or ... sham or pretend laser treatment. , Treatments were ... to laser and sham (inactive) laser acupuncture. , Researcher ...
(Date:10/1/2014)... and Physical Sciences Research Council (EPSRC) will focus ... control systems which run, for example, manufacturing plants, ... network. , The research will help understand ... the systems behind our critical national infrastructure. ... Systems (RITICS), based at Imperial College London, is ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Medical discovery first step on path to new painkillers 2Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2
... By studying the addition of sugars to proteins ... nervous system of insects, Karen Palter, researcher of ... to better understand neurodegenerative diseases in humans. Currently, ... projects exploring the glycosylation process that could eventually ...
... has increased in recent years, the Washington Post reports. ... and the American Society of Aesthetic Plastic Surgery, while ... medicine procedures, the number of blacks, Hispanics and Asians ... five years. In 2002, minorities accounted for 16% of ...
... Evidence is accumulating that depression is a risk factor ... Women's Health Watch. A recent study found that ... called selective serotonin reuptake inhibitors (SSRIs) had double the ... Other research points to depression itself as a source ...
... development and spread of drug-resistant tuberculosis (TB), the Stop TB ... Global Drug Facility, has provided anti-TB drug treatments for 10 ... ,"This is an important milestone, because getting anti-TB ... complete their treatment is the only way to break the ...
... the myriad strains of the human immunodeficiency virus (HIV) ... conducted at the Uniformed Services University of the Health ... variable, its prevention requires a vaccine effective enough to ... neutralise multiple viral strains. ,The latest ...
... Girls actress Lindsay Lohans father, Michael, believes now that his ... change her life completely. ,Lohan is currently ... in Malibu. ,Michael believes that Lohan can ... negative influence. ,"I'm glad she's there and ...
Cached Medicine News:Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 3Health News:Stop TB Partnership Has Provided Treatments for Ten Million People in Six Years 2
(Date:10/2/2014)... 1, 2014   Intarcia Therapeutics, Inc. today ... phase 3 clinical trials for ITCA 650 (exenatide, delivered ... osmotic mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, ... and safety of ITCA 650 in patients with type ... to be significantly superior to placebo for both 40 ...
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3NeuroCall Awarded Joint Commission Accreditation 2
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
Small pupil irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip and front notch, for engaging the iris, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, 0.6 mm dual sideports, 20 gauge. For the right handed surgeon....
Karate phaco chopper, semi-sharp, wedge shaped inferior edge with a pointed tip...
Phaco chopper, short (0.75 mm) pointed "quick chop" tip....
Medicine Products: